1[1]Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative[J]. Cancer Res, 1996, 56(1): 100-104. 被引量：1
2[2]Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells[J]. Nature Med, 1996, 2(5): 561-566. 被引量：1
3[3]Carroll M, Ohno JS, Tamura S, et al. CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins[J]. Blood, 1997, 90(12): 4947-4952. 被引量：1
4[4]Okuda K, Weisberg E, Gilliland DG, et al. ARG tyrosine kinase activity is inhibited by STI571[J]. Blood, 2001, 87(8): 2440-2448. 被引量：1
5[5]Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibitor of the Abl kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis[J]. Blood Cells Mol Dis, 1997,23(3): 380-394. 被引量：1
6[6]Dan S, Natio M, Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP57148[J]. Cell Death Differ, 1998, 5(8): 710-715 被引量：1
7[7]Oetzel C, Jonuleit T, Gotz A, et al. The tyrosine kinase inhibitor CGP57148(STI571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X[J]. Clin Cancer Res, 2000, 6(5): 1958-1968. 被引量：1
8[8]Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)[J].Clin Cancer Res, 1998, 4(7): 1661-1672. 被引量：1
9[9]Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells[J]. Blood, 1997, 90(9): 3691-3698. 被引量：1
10[10]Marley SB, Deininger MW, Davidson RJ, et al. The tyrosine kinase inhibitor STI571, like interferon-α, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia[J]. Exp Hematol, 2000,28(5): 551-557. 被引量：1
同被引文献13
1Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839(Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy[J]. Cancer Res, 2002;62:5749-54 被引量：1
2Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, et al. ZD1839(Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase[J]. Cancer Res,2002;62:2554-60 被引量：1
3Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo[J]. Molecular Cancer Therapeutics, 2001;1:85-94 被引量：1
4Fortunato C, Rosa C, Roberto B, Vincenzo D, Grazia P, Sabino De Placido, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839(Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor[J]. Clin Cancer Res,2000;6:2053-63 被引量：1
5Lichtner RB, Menrad A, Sommer A, Klar U, Schneider MR. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors[J]. Cancer Res,2001;61:5790-5 被引量：1
6Laurent FH, Andrew P,Thomas, Craig J, Elaine SE,et al. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors[J]. J Med Chem, 1999;42:5369-89 被引量：1
7Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, et al. Tyrosine kinase inhibitors, 15′4-(Phenylamino)quinazoline and 4-(phenylamino) pyrido[d] pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor[J]. J Med Chem,1999;42:1083-115 被引量：1
8Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase[J]. Clin Cancer Res, 2000;6:4885-92 被引量：1
9Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells[J]. Cancer Res,2001;61:7184-8 被引量：1
